Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate
For the Media Please cite this data as National Poison Data System, Americas Poison Centers. Any and all print, digital, social, or visual media using this data must include the following: You can reach your local poison center by calling Poison Help at 1-800-222-1222
Adjusting those formulations as your needs change, she adds
The mechanism also appears to preserve lean muscle mass, as the peptide does not promote protein catabolism or interfere with muscle protein synthesis pathways